Track market-moving stories before they get noisy

Aurora Investment Counsel acquired a new stake in shares of AptarGroup, Inc. (NYSE:ATR – Free Report) in the second quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 11,785 shares of the industrial products company’s stock, valued at approximately $1,475,000.

Other hedge funds have also added to or reduced their stakes in the company. First National Bank of Omaha purchased a new stake in shares of AptarGroup in the second quarter worth $1,061,000. Meeder Advisory Services Inc. purchased a new position in shares of AptarGroup in the 2nd quarter worth about $225,000. Nuance Investments LLC bought a new position in AptarGroup in the 2nd quarter worth about $22,933,000. BlackRock Inc. bought a new position in AptarGroup in the 2nd quarter worth about $768,464,000. Finally, Deutsche Bank AG purchased a new stake in AptarGroup during the 2nd quarter valued at about $14,903,000. 88.52% of the stock is owned by institutional investors.

Analysts Set New Price Targets ATR has been the subject of a number of analyst reports. Zacks Research upgraded shares of AptarGroup from a “strong sell” rating to a “hold” rating in a research note on Monday, May 4th. Wells Fargo & Company increased their price target on shares of AptarGroup from $145.00 to $155.00 and gave the company an “overweight” rating in a report on Monday, August 3rd. Bank of America raised shares of AptarGroup from a “neutral” rating to a “buy” rating and set a $173.00 price target for the company in a research report on Tuesday, July 14th. Raymond James Financial restated an “outperform” rating and issued a $160.00 price objective on shares of AptarGroup in a report on Wednesday, July 15th. Finally, Weiss Ratings reaffirmed a “hold (c)” rating on shares of AptarGroup in a research report on Wednesday, June 24th. Five equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $172.80.

Get Our Latest Stock Analysis on ATR Insiders Place Their Bets In other news, insider Hedi Tlili sold 8,854 shares of the business’s stock in a transaction on Monday, August 3rd. The shares were sold at an average price of $135.00, for a total value of $1,195,290.00. Following the transaction, the insider owned 15,379 shares of the company’s stock, valued at approximately $2,076,165. The trade was a 36.54% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Stephan B. Tanda sold 9,838 shares of the company’s stock in a transaction on Monday, August 3rd. The stock was sold at an average price of $136.16, for a total transaction of $1,339,542.08. Following the transaction, the chief executive officer owned 238,729 shares of the company’s stock, valued at approximately $32,505,340.64. This represents a 3.96% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 22,247 shares of company stock worth $2,935,161 in the last three months. 0.73% of the stock is owned by company insiders.

AptarGroup Trading Up 1.0% Shares of NYSE:ATR opened at $133.00 on Thursday. The stock has a 50 day moving average of $128.54 and a 200 day moving average of $127.53. The company has a market cap of $8.46 billion, a PE ratio of 24.05, a price-to-earnings-growth ratio of 3.24 and a beta of 0.39. AptarGroup, Inc. has a 12-month low of $103.23 and a 12-month high of $146.91. The company has a current ratio of 1.61, a quick ratio of 1.10 and a debt-to-equity ratio of 0.42.

AptarGroup (NYSE:ATR – Get Free Report) last released its earnings results on Thursday, July 30th. The industrial products company reported $1.42 EPS for the quarter, topping analysts’ consensus estimates of $1.35 by $0.07. The company had revenue of $1.03 billion for the quarter, compared to analysts’ expectations of $1.01 billion. AptarGroup had a net margin of 9.22% and a return on equity of 13.31%. The firm’s revenue was up 6.3% compared to the same quarter last year. During the same quarter last year, the business earned $1.66 EPS. AptarGroup has set its Q3 2026 guidance at 1.450-1.530 EPS. As a group, equities research analysts expect that AptarGroup, Inc. will post 5.48 EPS for the current year.

AptarGroup Dividend Announcement The firm also recently declared a quarterly dividend, which will be paid on Thursday, August 20th. Shareholders of record on Thursday, July 30th will be paid a $0.48 dividend. This represents a $1.92 annualized dividend and a yield of 1.4%. The ex-dividend date is Thursday, July 30th. AptarGroup’s dividend payout ratio is presently 34.72%.

About AptarGroup (Free Report)

AptarGroup, Inc is a global provider of advanced dispensing, sealing and protection solutions for consumer and pharmaceutical markets. The company designs and manufactures a broad portfolio of products that enable the controlled delivery of liquids, gels, powders and aerosols. Its customer base spans beauty and personal care, home care, food and beverage, and pharmaceutical sectors, where innovation in packaging and drug‐delivery devices drives brand differentiation and regulatory compliance.

In the consumer markets, AptarGroup offers pumps, actuators, valves, closures and specialized bottles engineered for precision, convenience and sustainability.

Featured Stories Five stocks we like better than AptarGroup Bloom Energy’s AI Surge Meets a Valuation Reality Check Target Is Winning Shoppers Back—Can the Rally Reach $180? IonQ’s Space Contract Points to a New Frontier for Quantum Investors Is Apple’s AI Strategy Smarter Than Skeptics Think? Want to see what other hedge funds are holding ATR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AptarGroup, Inc. (NYSE:ATR – Free Report).

Receive News & Ratings for AptarGroup Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AptarGroup and related companies with MarketBeat.com's FREE daily email newsletter.

AptarGroup NYSE: ATR reported second-quarter sales growth across each of its three segments and adjusted earnings per share above its guidance range, supported by stronger-than-expected performance in its Pharma business. The company also said President and CEO Stephan Tanda will retire later this year, with President and CEO Designate Gael Touya set to assume the CEO role on Sept. 1.

Reported second-quarter sales increased 6% to approximately $1 billion, a quarterly record, while core sales, which exclude currency effects and acquisitions, rose 1% from a year earlier. Adjusted EBITDA declined 3% to $213 million, and adjusted EBITDA margin fell to 20.7% from 22.6% in the prior-year period. Adjusted EPS was $1.42, compared with $1.68 a year earlier at comparable exchange rates.

Get AptarGroup alerts:

Chief Financial Officer Vanessa Kanu said the earnings decline reflected lower emergency medicine sales in Pharma, operating challenges in Beauty and Closures, higher depreciation and amortization related to investments and acquisitions, and higher interest expense.

Pharma Growth Excluding Emergency Medicine Pharma core sales rose 1% in the quarter, affected by an anticipated decline in emergency medicine sales. Aptar expects emergency medicine sales to decline by about $65 million during fiscal 2026. Kanu said roughly two-thirds of that headwind occurred during the first half, with most of it occurring in the second quarter. The remaining portion is expected primarily in the third quarter, with the year-over-year impact expected to abate by the fourth quarter.

Excluding emergency medicine, Pharma core sales rose 8%. Prescription core sales declined 7% overall but increased 8% excluding emergency medicine, driven by central nervous system treatments and asthma and COPD applications. Consumer healthcare core sales increased 15%, supported by demand for nasal decongestants, eye-care products, dermal solutions and tooling. Injectables core sales rose 9%, reflecting demand for elastomeric components used in GLP-1 therapies, biologics and vaccines.

Pharma’s adjusted EBITDA margin was 33.6%, down 180 basis points from the prior year, largely because of the mix effect from lower high-margin emergency medicine sales. Kanu said the segment’s margin would have improved year over year excluding emergency medicine.

Management also pointed to continued pipeline activity in Annex I compliance, GLP-1 and biologics projects. Touya said the company has completed its larger investment phase at its Congers, New York, injectable manufacturing site and that customer audits, inspections and validations are supporting growth.

The company highlighted several technology developments, including an approved U.S. patent application for N-Sorb, an active-material solution intended to address nitrosamine impurities in pharmaceutical products. Aptar also introduced a collaborative system framework for injectable therapies designed to provide customers with earlier information on the performance of assembled injection systems.

In respiratory delivery, Aptar noted regulatory approvals involving products that use its inhaler technologies. It also cited Chiesi’s U.K. approval for what Aptar described as the first pressurized metered-dose inhaler using HFA-152a, a next-generation lower-global-warming-potential propellant.

Beauty and Closures See Sales Growth, Margin Pressure Beauty core sales increased 1%, as demand for dispensing systems and higher input-cost pass-throughs offset lower tooling sales. Fragrance, facial skincare and color cosmetics sales grew 2%, led by prestige fragrance pumps and color cosmetics. Personal care sales were flat, as hair-care demand did not fully offset lower tooling sales.

Beauty’s adjusted EBITDA margin was 12.2%, down 190 basis points year over year, though it improved sequentially from the first quarter. Kanu attributed the year-over-year decline to lower volumes, unfavorable mix and the timing of resin and other inflationary pass-throughs. She said a delay in Beauty pricing pass-throughs reduced the segment’s quarterly margin by roughly 80 to 90 basis points and is expected to be resolved in the third quarter.

During the question-and-answer session, Tanda said Aptar had experienced weak sales in Brazil, where he said two major customers can shift market share. He said the company’s Beauty turnaround in Europe has reached its target range, while Asia is performing above that range, but the Americas have underperformed because of operational challenges in North America and market weakness in Brazil. Touya said he is reviewing the business with a “fresh perspective” and plans to engage with customers and operations teams before detailing further actions.

Closures core sales increased 4%. Food sales declined 1% due to lower tooling sales, partially offset by demand for sauce and condiment dispensing closures. Beverage sales rose 14%, driven by bottled water and functional sports drinks. The segment’s adjusted EBITDA margin was 14.9%, down 200 basis points, due to the ramp-up of new production lines and a maintenance initiative that management said is making sequential progress.

Cash Flow, Capital Returns and Outlook For the first six months of 2026, reported sales rose 8% and core sales increased 1%. Adjusted EBITDA was unchanged at $401 million, while adjusted EBITDA margin declined 170 basis points to 20%. Adjusted EPS fell 12% to $2.61.

Year-to-date free cash flow increased by $8 million to $99 million, consisting of $222 million in cash from operations less $123 million in capital expenditures, net of government grants. Aptar returned $212 million to shareholders through dividends and share repurchases during the first half, including the repurchase of 1.1 million shares for $150 million.

The company ended the quarter with $190 million in cash, $1.2 billion in net debt and a leverage ratio of 1.49 times. Kanu said Aptar expects third-quarter adjusted EPS of $1.45 to $1.53, based on an effective tax rate of 22.5% to 24.5% and a euro-to-U.S.-dollar exchange rate of $1.14. Full-year capital investments are expected to range from $260 million to $280 million, while depreciation and amortization expense is projected at $310 million to $320 million.

Touya said Aptar expects growth across all three segments, citing demand in Pharma, continued momentum in Closures and improving trends in Beauty. As he prepares to take over as CEO, Touya said his priorities will be to drive profitable growth, execute consistently and allocate capital thoughtfully.

About AptarGroup (NYSE:ATR)AptarGroup, Inc is a global provider of advanced dispensing, sealing and protection solutions for consumer and pharmaceutical markets. The company designs and manufactures a broad portfolio of products that enable the controlled delivery of liquids, gels, powders and aerosols. Its customer base spans beauty and personal care, home care, food and beverage, and pharmaceutical sectors, where innovation in packaging and drug‐delivery devices drives brand differentiation and regulatory compliance.

In the consumer markets, AptarGroup offers pumps, actuators, valves, closures and specialized bottles engineered for precision, convenience and sustainability.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to [email protected].

Should You Invest $1,000 in AptarGroup Right Now?Before you consider AptarGroup, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and AptarGroup wasn't on the list.

While AptarGroup currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The AI wave will soon hit public markets with Anthropic and OpenAI set to go public later this year. However, you don't have to wait to invest. This report shows seven AI stocks that you can buy today while the big model providers get ready to go public.

Get This Free Report

CRYSTAL LAKE, Ill.--(BUSINESS WIRE)--AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing, today announced that the Board declared a quarterly cash dividend of $0.48 per share. The payment date is August 20, 2026, to stockholders of record as of July 30, 2026.

As previously announced, Aptar will hold a conference call on Friday, July 31, 2026, at 8:00 a.m. Central Time to discuss the Company’s second quarter results for 2026. The call will last approximately one hour. Interested parties are invited to listen to a live webcast by visiting the Investors page at www.aptar.com. A replay of the conference call can also be accessed for a limited time on the Investors page of the website.

About Aptar

Aptar is a global leader in drug delivery, dosing and protection technologies, and consumer product dispensing. Aptar partners with the world’s top healthcare and consumer brands to deliver medicines and create exceptional user experiences. Serving diverse markets, from pharmaceutical to beauty to food and beverage, Aptar combines market expertise with proprietary design, engineering and science to develop innovative solutions that help improve lives worldwide. Headquartered in Crystal Lake, Illinois, Aptar employs 14,000 dedicated people across 20 countries. Learn more at http://www.aptar.com.

This press release contains forward-looking statements, including with regard to the payment of the quarterly cash dividend. Expressions or future or conditional verbs such as “will” are intended to identify such forward-looking statements. Forward-looking statements are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and are based on our beliefs as well as assumptions made by and information currently available to us. Accordingly, our actual results may differ materially from those expressed or implied in such forward-looking statements due to known or unknown risks and uncertainties that exist in our operations and business environment including, but not limited to: the successful integration of acquisitions; the regulatory environment; and competition, including technological advances. For additional information on these and other risks and uncertainties, please see our filings with the Securities and Exchange Commission, including the discussion under “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Form 10-Ks and Form 10-Qs. We undertake no obligation to update any forward-looking statements, whether as a result of new information, future events or otherwise.

More News From AptarGroup, Inc.